US › Healthcare

Relmada Therapeutics Inc (RLMD)

US · Healthcare · Biotechnology

$3.10-3.12%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-12.9M

EPS

$-0.11

EPS estimate

$-0.21

EPS came in at -0.11 against a street estimate of -0.21 — a beat of 47.6%.

Key statistics

Market cap

$330.7M

Forward P/E

0.0

P/B

1.95

Book value

$1.94

EPS (TTM)

$-0.91

52-week high

$8.00

52-week low

$1.97

50-day MA

$4.13

200-day MA

$5.40

Beta

0.51

Analyst view

Analysts rate Relmada Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $10.75.

Shareholding

Insiders

3.23%

Institutions

94.66%

Largest institutional holders

Fund	Stake
Jupiter Topco LLC	10.47%
HHG PLC	10.37%
BlackRock Inc	6.96%
Squadron Capital Management LLC	6.89%
VR Adviser, LLC	6.42%
Spruce Street Capital LP	5.99%
Adage Capital Partners Gp LLC	4.47%
Vanguard Capital Management, LLC	4.18%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Relmada Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.